Publications
- The significance of enzyme and transporter polymorphisms for imatinib plasma levels and achieving an optimal response in chronic myeloid leukemia patients2018 | Faculty of Medicine in Hradec Králové
- Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment2017 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine, Faculty of Science
- Experience with ruxolitinib in the treatment of myelofibrosis and polycythaemia vera at Czech haematological institutions2017 | Faculty of Medicine in Hradec Králové
- Long-term treatment results of chronic myelomonocytic leukaemia in selected haematological centres2017 | Faculty of Medicine in Hradec Králové
- Improvement of Anaemia in Patients with Primary Myelofibrosis by Low-Dose Thalidomide and Prednisone2016 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine
- Melodysplastic syndrome2016 | Faculty of Medicine in Hradec Králové
- Diagnosis and treatment of chronic myelomonocytic leukemia - a view from clinical practice2016 | Publication without faculty affiliation
- Lenalidomide treatment in myelodysplastic syndrome with 5q deletion - Czech MDS group experience2015 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine, Second Faculty of Medicine
- Impact of age on the clinical response of patients with CML treated with imatinib2015 | Faculty of Medicine in Hradec Králové
- Role of ruxolitinib in the treatment of primary myelofibrosis2015 | Faculty of Medicine in Hradec Králové
Loading network view...